Učitavanje...
Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC
The aim of this study was to evaluate the efficacy and safety of gefitinib as a first-line therapy for advanced non-small cell lung cancer (NSCLC). Patients with advanced NSCLC who did not tolerate or who refused chemotherapy received 250 mg/day of gefitinib orally as first-line therapy. A total of...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
D.A. Spandidos
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3389644/ https://ncbi.nlm.nih.gov/pubmed/22783392 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2012.631 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|